Pharma BD Deal Intelligence

LaunXP International Co., Ltd. / Apollomics Inc.

2025 · Licensing/Option · $60M · Complete

Apollomics granted LaunXP International rights to develop and commercialize vebreltinib, its c-Met inhibitor, in combination with an EGFR inhibitor in Asia excluding mainland China, Hong Kong and Macau, for NSCLC and other tumor types. Apollomics receives $10 million in upfront payments within 60 days of the agreement date, is eligible for up to $50 million in regulatory and pre-commercial milestones, and royalties on net sales. LaunXP is primarily responsible for development in its territory.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals